Critical Review: Solana (NASDAQ:HSDT) versus Teleflex (NYSE:TFX)

Solana (NASDAQ:HSDT) and Teleflex (NYSE:TFX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Risk and Volatility

Solana has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Insider and Institutional Ownership

18.6% of Solana shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Comparatively, 0.7% of Teleflex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Solana and Teleflex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Teleflex	-35.88%	13.29%	6.55%

Valuation & Earnings

This table compares Solana and Teleflex”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02 million	18.43	-$40.89 million	($109.67)	-0.02
Teleflex	$1.99 billion	2.86	-$905.64 million	($22.80)	-5.65

Solana has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Solana and Teleflex, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	1	1	2.50
Teleflex	1	5	3	0	2.22

Solana currently has a consensus target price of $3.50, indicating a potential upside of 84.21%. Teleflex has a consensus target price of $144.00, indicating a potential upside of 11.79%. Given Solana’s stronger consensus rating and higher possible upside, research analysts plainly believe Solana is more favorable than Teleflex.

Summary

Solana beats Teleflex on 8 of the 15 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.